US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Centessa Pharmaceuticals plc

< Previous 1 2 Next >
News headline image
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
< Previous 1 2 Next >